MISSION

The Brain Tumour Group initiates and conducts research to challenge, re-define and develop standards of care in controversial areas of diagnostic and therapeutic neuro-oncology. The Group is especially focused on diffuse gliomas of adulthood of World Health Organisation grades II to IV and, in recent years, also meningioma.

PRACTICE CHANGING RESEARCH

  • Radiation Oncology Group

    EORTC 228544 – A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma.

    EORTC demonstrated that providing patients with ‘low’-dose (45 Gy) radiotherapy, was equally good as the ‘high’-dose (59.4 Gy) radiotherapy provided. This meant that the ‘low’-dose not only improved tumor control but also reduced toxicity to low-grade glioma patients. This study contributed to determining the standard radiotherapy dose.

  • Radiation Oncology Group

    EORTC 22845 – Phase III trial of radiation therapy vs no radiation therapy for cerebral gliomas (low grade astrocytoma and oligodendroglioma) of the adult.

    Joint study of the EORTC Radiotherapy Cooperative Group, the EORTC Brain Tumor Cooperative Group and the Medical Research Council (UK).

    EORTC found that post-operative radiotherapy significantly improved disease-free survival in adult patients with low-grade glioma.

    READ MORE

  • Brain Group

    EORTC 26981/22981 – Concomitant and adjuvant Temozolomide and Radiotherapy for newly diagnosed glioblastoma multiforme.

    A randomized phase III study.

    A landmark EORTC study that found that the combination of the chemotherapy drug temozolomide (TMZ) and radiotherapy, improved survival rates without sacrificing health-related quality of life (HRQOL) scores, in patients with glioblastoma (GBM). This combination treatment became the standard of care for newly diagnosed glioblastoma patients worldwide. This study also identified the MGMT gene promoter methylation as the first predictive marker in brain tumors and introduced the concept of personalized treatment into neuro-oncology.

    READ MORE

  • Brain Group

    EORTC 26951 – Phase III study of adjuvant Procarbazine, CCNU and Vincristine chemotherapy in patients with highly anaplastic oligodendroglioma (randomized).

    EORTC study assessing the effectiveness of the combination treatment of chemotherapy (PCV) and radiotherapy in patients with anaplastic oligodendroglioma (a rare brain tumour). Results show that this combination treatment slightly improves progression free survival but negatively impact patients’ health-related quality of life (HRQOL) scores. This result provided more insight into the potential benefit of early, aggressive treatment.

    READ MORE

  • Radiation Oncology Group

    EORTC 22952 – No Radiotherapy versus Whole Brain Radiotherapy for 1 to 3 Brain Metastases from Solid Tumor after Surgical Resection or Radiosurgery.

    A Randomized Phase III Trial.

    The role of whole-brain radiotherapy (WBRT) after either surgical resection or radiosurgery of brain metastases has been debated for many years. Previous studies have established a marginal advantage of WBRT for progression-free survival in patients with stable, solid brain tumors. However, because brain metastases cannot be cured and only symptoms can be treated, maintenance of health-related quality of life (HRQOL) is very important. Therefore, this EORTC study found that additional whole-brain radiotherapy (WBRT) after surgery or radiosurgery negatively impacts heath-related quality of life in patients with brain metastases. These results help to better inform patients and oncologists on treatment options.

    READ MORE

  • Radiation Oncology Group

    EORTC 22033/26033 – Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss.

    A phase III study.

    EORTC found that postoperative chemotherapy and radiotherapy were equally as effective in prolonging progression-free survival in patients with low-grade glioma.

    READ MORE

  • Brain Group

    EORTC 26053/22054 (CATNON) – Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma.

    The CATNON intergroup trial.

    Both radiation therapy and chemotherapy drugs work by killing or stopping the growth of cancerous tumor cells. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells and chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The chemotherapy drug, temozolomide (TMZ), is often used to treat patients with anaplastic glioma. However, anaplastic glioma patients with specific tumor variant –1p/19q non-co-deleted tumors– are associated with lower response to chemotherapy and worse prognosis. Therefore this EORTC study assessed whether giving TMZ during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma. The interim analysis indicated that following radiotherapy with TMZ is associated with better survival benefits in patients with newly diagnosed non-co-deleted anaplastic glioma. Further analysis of the role of concurrent temozolomide treatment and molecular factors is needed.

    READ MORE

  • Brain Group

    EORTC 26101 – Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.

    Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.

    EORTC study comparing two treatment regimens in patients with reoccurring glioblastoma (GBM), found that the combination treatment of bevacizumab and lomustine, did not provide additional survival benefit for those patients. The MRI images however collected in this trial, were analyzed using an automated quantitative tumour response assessment, called artificial neural networks (ANN). The study showed that using ANN, enabled objective, uniform, and automated assessment of tumour response that helps overcome the limitations of manual, human assessment of MRI images. This study could ultimately serve as a blueprint for the application of ANN in radiology to improve clinical decision making and tumor assessment.

    READ MORE

  • Brain Group

    ORTC 26071/22072 – Cilengitide in subjects with newly diagnosed glioblastoma and methylated MGMT promoter gene- a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC)

    Building off of the results of previous clinical research, this EORTC study analyzed the MGMT methylation cutoff in clinical trials as a prognostic factor in how patients with glioblastoma (GBM) respond to treatment. It found that patients with low MGMT methylation have some sensitivity to temozolomide (TMZ) chemotherapy treatment, hence the lower safety margin should be considered for selecting patients with unmethylated GBM into trials omitting temozolomide.

    READ MORE

  • Brain Group

    EORTC 1320 – Trabectedin for recurrent grade II or III meningioma.

    A randomized phase II study of the EORTC Brain Tumor Group.

    EORTC study assessed the effectiveness of an anti-tumour drug, trabectedin, for grade II or III meningioma patients (types of aggressive brain tumours), and found no improvement in progression free or overall survival for these patients. Results from this study can serve as a benchmark for future clinical trials investigating trabectedin.

    READ MORE

  • Brain Group

    EORTC 1410 – INTELLANCE 2: ABT 414 alone or ABT 414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma.

    A randomized phase II study of the EORTC Brain Tumor Group.

    EORTC study comparing two treatment regimens for patients with recurring glioblastoma. About 50% of patients with recurrent glioblastoma (rGBM) have tumors with epidermal growth factor receptor (EGFR), which increases tumor growth. Results showed that adding the antibiotic drug ABT414 to the standard chemotherapy with temozolomide (TMZ), was an effective treatment in patients with EGFR amplified recurrent glioblastoma, especially in patients relapsing well after the end of first-line TMZ treatment.

    READ MORE

  • Oct-96
  • Sep-05
  • Dec-05
  • Dec-07
  • Jan-13
  • Nov-16
  • Aug-17
  • Nov-17
  • Mar-19
  • May-19
  • Nov-19

LATEST PUBLICATIONS

Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up